{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T17:21:00Z","timestamp":1788542460069,"version":"build-2803163510"},"reference-count":12,"publisher":"Japanese Society of Internal Medicine","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2019,6,1]]},"DOI":"10.2169\/internalmedicine.1956-18","type":"journal-article","created":{"date-parts":[[2019,1,31]],"date-time":"2019-01-31T22:38:15Z","timestamp":1548974295000},"page":"1635-1638","source":"Crossref","is-referenced-by-count":31,"title":["Pembrolizumab-induced Ocular Myasthenia Gravis with Anti-titin Antibody and Necrotizing Myopathy"],"prefix":"10.2169","volume":"58","author":[{"given":"Asako","family":"Onda","sequence":"first","affiliation":[{"name":"Department of Neurology, The Jikei University Kashiwa Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Miyagawa","sequence":"additional","affiliation":[{"name":"Department of Neurology, The Jikei University Kashiwa Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoko","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, The Jikei University Kashiwa Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mina","family":"Gochi","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, The Jikei University Kashiwa Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masamichi","family":"Takagi","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, The Jikei University Kashiwa Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichizo","family":"Nishino","sequence":"additional","affiliation":[{"name":"Department of Neuromuscular Research, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeaki","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Neurology, The Keio University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chizuko","family":"Oishi","sequence":"additional","affiliation":[{"name":"Department of Neurology, The Kyorin University Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Yaguchi","sequence":"additional","affiliation":[{"name":"Department of Neurology, The Jikei University Kashiwa Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","unstructured":"1. Miyauchi E, Inoue A. Immune checkpoint therapy for non-small-cell lung cancer. Gan To Kagaku Ryoho 43: 666-671, 2016 (in Japanese, Abstract in English)."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Kao JC, Liao B, Markovic SN, et al. Neurological complications associated with anti-programmed death 1 (PD-1) antibodies. JAMA Neurol 74: 1216-1222, 2017.","DOI":"10.1001\/jamaneurol.2017.1912"},{"key":"3","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1212\/WNL.0000000000004359","volume":"89","author":"S Suzuki","year":"2017","unstructured":"3. Suzuki S, Ishikawa N, Konoeda F, et al. Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan. Neurology 89: 1127-1134, 2017.","journal-title":"Neurology","ISSN":"https:\/\/id.crossref.org\/issn\/0028-3878","issn-type":"print"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Polat P, Donofrio PD. Myasthenia gravis induced by nivolumab therapy in a patient with non-small-cell lung cancer. Muscle Nerve 54: 507, 2016.","DOI":"10.1002\/mus.25163"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Nguyen BH, Kuo J, Budiman A, Christie H, Ali S. Two cases of clinical myasthenia gravis associated with pembrolizumab use in responding melanoma patients. Melanoma Res 27: 152-154, 2017.","DOI":"10.1097\/CMR.0000000000000310"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Suzuki S, Utsugisawa K, Nagane Y, Suzuki N. Three types of striational antibodies in myasthenia gravis. Autoimmune Dis, 2011 (Epub ahead of print).","DOI":"10.4061\/2011\/740583"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Bilen MA, Subudhi SK, Gao J, Tannir NM, Tu SM, Sharma P. Acute rhabdomyolysis with severe polymyositis following ipilimumab-nivolumab treatment in a cancer patient with elevated anti-striated muscle antibody. J Immunother Cancer 4: 36, 2016.","DOI":"10.1186\/s40425-016-0139-8"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Norwood TG, Westbrook BC, Johnson DB, et al. Smoldering myocarditis following immune checkpoint blockade. J Immunother Cancer 5: 91, 2017.","DOI":"10.1186\/s40425-017-0296-4"},{"key":"9","unstructured":"9. Liewluck T, Kao JC, Mauermann ML. PD-1 inhibitor-associated myopathies: emerging immune-mediated myopathies. J Immunother 41: 208-211, 2018."},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Hurst RL, Gooch CL. Muscle-specific receptor tyrosine kinase (MuSK) myasthenia gravis. Curr Neurol Neurosci Rep 16: 61, 2016.","DOI":"10.1007\/s11910-016-0668-z"},{"key":"11","unstructured":"11. Gonzalez NL, Puwanant A, Lu A, Marks SM, \u017divkovi\u0107 SA. Myasthenia triggered by immune checkpoint inhibitors: new case and literature review. Neuromuscul Disord 27: 266-268, 2017."},{"key":"12","unstructured":"12. Kim NR, Suh YL. Tubular aggregate myopathy: a case report. J Korean Med Sci 18: 135-140, 2003."}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/58\/11\/58_1956-18\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T04:06:05Z","timestamp":1559361965000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/58\/11\/58_1956-18\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,1]]},"references-count":12,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.1956-18","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,1]]}}}